UNSPSC 51162414: Ephedrine/potassium iodide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.

UNSPSC 51162414 Ephedrine/potassium iodide is a Commodity code that does not align with the recent state and local solicitations posted under this designation. The two opportunities in the source—one from Seminole County, Florida for naloxone and drug deactivation systems, and one from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products—involve pharmaceutical procurement broadly but fall outside the specific scope of ephedrine and potassium iodide products. The naloxone procurement targets emergency response and community health initiatives, while the MMCAP RFP covers a wide range of generic pharmaceuticals and OTC items distributed across state and local government facilities, neither of which directly addresses ephedrine or potassium iodide procurement as the code's name would suggest.

Activity under this code appears minimal or mislabeled in recent state and local procurement. The geographic spread suggested by the source includes Florida and Minnesota (through MMCAP, which extends to Oregon and other participating states), but the pharmaceutical scope mismatch means these opportunities do not constitute reliable signals for ephedrine/potassium iodide demand. Seminole County issued IFB 60459723LAS for naloxone and drug deactivation systems with a July 26, 2023 response deadline, while MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 for multi-source pharmaceuticals with a March 26, 2026 due date. Business development professionals should verify whether ephedrine/potassium iodide procurement is actually occurring under this code or whether the coding assignment reflects a broader pharmaceutical classification that does not capture this Commodity's actual market activity in state and local government.